nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—Erlotinib—pancreatic cancer	0.366	1	CrCtD
Gefitinib—Vandetanib—Erlotinib—pancreatic cancer	0.181	1	CrCrCtD
Gefitinib—EGFR—pancreatic cancer	0.0969	1	CbGaD
Gefitinib—SBK1—Sunitinib—pancreatic cancer	0.0234	0.0883	CbGbCtD
Gefitinib—MKNK1—Erlotinib—pancreatic cancer	0.0204	0.077	CbGbCtD
Gefitinib—LOC400927-CSNK1E—Sunitinib—pancreatic cancer	0.0169	0.0639	CbGbCtD
Gefitinib—CSNK1E—Sunitinib—pancreatic cancer	0.0169	0.0639	CbGbCtD
Gefitinib—CHEK2—Sunitinib—pancreatic cancer	0.0169	0.0639	CbGbCtD
Gefitinib—IRAK4—Sunitinib—pancreatic cancer	0.0135	0.0507	CbGbCtD
Gefitinib—HIPK4—Erlotinib—pancreatic cancer	0.0131	0.0492	CbGbCtD
Gefitinib—EPHA6—Erlotinib—pancreatic cancer	0.0131	0.0492	CbGbCtD
Gefitinib—EGFR—Erlotinib—pancreatic cancer	0.0117	0.0442	CbGbCtD
Gefitinib—STK10—Erlotinib—pancreatic cancer	0.0117	0.0442	CbGbCtD
Gefitinib—MAP2K5—Erlotinib—pancreatic cancer	0.0107	0.0403	CbGbCtD
Gefitinib—MAP3K19—Erlotinib—pancreatic cancer	0.00982	0.037	CbGbCtD
Gefitinib—IRAK1—Sunitinib—pancreatic cancer	0.00973	0.0367	CbGbCtD
Gefitinib—HIPK4—Sunitinib—pancreatic cancer	0.0086	0.0324	CbGbCtD
Gefitinib—EGFR—Docetaxel—pancreatic cancer	0.00777	0.0293	CbGbCtD
Gefitinib—STK10—Sunitinib—pancreatic cancer	0.00773	0.0291	CbGbCtD
Gefitinib—MAP2K5—Sunitinib—pancreatic cancer	0.00704	0.0265	CbGbCtD
Gefitinib—MAP3K19—Sunitinib—pancreatic cancer	0.00647	0.0244	CbGbCtD
Gefitinib—ORM1—Erlotinib—pancreatic cancer	0.00318	0.012	CbGbCtD
Gefitinib—CYP1A1—Dacarbazine—pancreatic cancer	0.00264	0.00997	CbGbCtD
Gefitinib—ABCG2—Tamoxifen—pancreatic cancer	0.00228	0.00859	CbGbCtD
Gefitinib—CYP1A1—Tamoxifen—pancreatic cancer	0.0021	0.00793	CbGbCtD
Gefitinib—ABCG2—Erlotinib—pancreatic cancer	0.00194	0.0073	CbGbCtD
Gefitinib—CYP1A1—Erlotinib—pancreatic cancer	0.00179	0.00674	CbGbCtD
Gefitinib—ABCG2—Irinotecan—pancreatic cancer	0.00175	0.0066	CbGbCtD
Gefitinib—ABCG2—Fluorouracil—pancreatic cancer	0.00168	0.00633	CbGbCtD
Gefitinib—ALB—Erlotinib—pancreatic cancer	0.00134	0.00504	CbGbCtD
Gefitinib—ABCG2—Docetaxel—pancreatic cancer	0.00128	0.00483	CbGbCtD
Gefitinib—ABCG2—Sunitinib—pancreatic cancer	0.00128	0.00481	CbGbCtD
Gefitinib—CYP3A5—Tamoxifen—pancreatic cancer	0.00126	0.00476	CbGbCtD
Gefitinib—ALB—Irinotecan—pancreatic cancer	0.00121	0.00455	CbGbCtD
Gefitinib—ALB—Fluorouracil—pancreatic cancer	0.00116	0.00436	CbGbCtD
Gefitinib—ORM1—bile—pancreatic cancer	0.00116	0.19	CbGeAlD
Gefitinib—CYP3A5—Erlotinib—pancreatic cancer	0.00107	0.00405	CbGbCtD
Gefitinib—CYP2C19—Tamoxifen—pancreatic cancer	0.00102	0.00384	CbGbCtD
Gefitinib—CYP3A5—Irinotecan—pancreatic cancer	0.00097	0.00365	CbGbCtD
Gefitinib—ABCG2—Doxorubicin—pancreatic cancer	0.000956	0.0036	CbGbCtD
Gefitinib—CYP2C9—Tamoxifen—pancreatic cancer	0.000847	0.00319	CbGbCtD
Gefitinib—ABCB1—Tamoxifen—pancreatic cancer	0.000822	0.0031	CbGbCtD
Gefitinib—CYP2D6—Tamoxifen—pancreatic cancer	0.000774	0.00292	CbGbCtD
Gefitinib—CYP3A5—Docetaxel—pancreatic cancer	0.000711	0.00268	CbGbCtD
Gefitinib—ABCB1—Gemcitabine—pancreatic cancer	0.000708	0.00267	CbGbCtD
Gefitinib—CYP3A5—Sunitinib—pancreatic cancer	0.000707	0.00267	CbGbCtD
Gefitinib—ABCB1—Erlotinib—pancreatic cancer	0.000699	0.00263	CbGbCtD
Gefitinib—CYP2D6—Erlotinib—pancreatic cancer	0.000658	0.00248	CbGbCtD
Gefitinib—ABCB1—Irinotecan—pancreatic cancer	0.000631	0.00238	CbGbCtD
Gefitinib—CYP2C9—Fluorouracil—pancreatic cancer	0.000624	0.00235	CbGbCtD
Gefitinib—CYP3A4—Tamoxifen—pancreatic cancer	0.000492	0.00186	CbGbCtD
Gefitinib—ABCB1—Docetaxel—pancreatic cancer	0.000462	0.00174	CbGbCtD
Gefitinib—ABCB1—Sunitinib—pancreatic cancer	0.00046	0.00174	CbGbCtD
Gefitinib—CHEK2—Paclitaxel—Docetaxel—pancreatic cancer	0.000448	0.608	CbGdCrCtD
Gefitinib—CYP3A4—Erlotinib—pancreatic cancer	0.000419	0.00158	CbGbCtD
Gefitinib—CSNK1E—islet of Langerhans—pancreatic cancer	0.000389	0.0639	CbGeAlD
Gefitinib—IRAK4—islet of Langerhans—pancreatic cancer	0.000383	0.0629	CbGeAlD
Gefitinib—CYP3A4—Irinotecan—pancreatic cancer	0.000378	0.00143	CbGbCtD
Gefitinib—MKNK2—islet of Langerhans—pancreatic cancer	0.000357	0.0586	CbGeAlD
Gefitinib—IRAK1—islet of Langerhans—pancreatic cancer	0.000357	0.0586	CbGeAlD
Gefitinib—ABCB1—Doxorubicin—pancreatic cancer	0.000345	0.0013	CbGbCtD
Gefitinib—CYP2D6—Doxorubicin—pancreatic cancer	0.000325	0.00122	CbGbCtD
Gefitinib—ORM1—gall bladder—pancreatic cancer	0.000321	0.0527	CbGeAlD
Gefitinib—Lapatinib—EGFR—pancreatic cancer	0.000314	0.215	CrCbGaD
Gefitinib—ALB—gall bladder—pancreatic cancer	0.000281	0.0462	CbGeAlD
Gefitinib—CYP3A4—Docetaxel—pancreatic cancer	0.000277	0.00104	CbGbCtD
Gefitinib—CYP3A4—Sunitinib—pancreatic cancer	0.000276	0.00104	CbGbCtD
Gefitinib—CSNK1E—pancreas—pancreatic cancer	0.000273	0.0449	CbGeAlD
Gefitinib—ERBB3—pancreas—pancreatic cancer	0.000264	0.0433	CbGeAlD
Gefitinib—MKNK2—pancreas—pancreatic cancer	0.000251	0.0412	CbGeAlD
Gefitinib—IRAK1—pancreas—pancreatic cancer	0.000251	0.0412	CbGeAlD
Gefitinib—CSNK1E—digestive system—pancreatic cancer	0.000233	0.0383	CbGeAlD
Gefitinib—ERBB3—digestive system—pancreatic cancer	0.000225	0.037	CbGeAlD
Gefitinib—Afatinib—EGFR—pancreatic cancer	0.000223	0.152	CrCbGaD
Gefitinib—MKNK2—digestive system—pancreatic cancer	0.000214	0.0352	CbGeAlD
Gefitinib—MKNK1—digestive system—pancreatic cancer	0.000211	0.0347	CbGeAlD
Gefitinib—CYP3A4—Doxorubicin—pancreatic cancer	0.000207	0.000779	CbGbCtD
Gefitinib—STK10—digestive system—pancreatic cancer	0.000174	0.0286	CbGeAlD
Gefitinib—Erlotinib—EGFR—pancreatic cancer	0.000157	0.108	CrCbGaD
Gefitinib—Vandetanib—SRC—pancreatic cancer	0.000154	0.106	CrCbGaD
Gefitinib—CHEK2—Doxorubicin—Epirubicin—pancreatic cancer	0.00015	0.204	CbGdCrCtD
Gefitinib—Vandetanib—KDR—pancreatic cancer	0.000145	0.0992	CrCbGaD
Gefitinib—Bosutinib—SRC—pancreatic cancer	0.000144	0.0988	CrCbGaD
Gefitinib—CHEK2—Epirubicin—Doxorubicin—pancreatic cancer	0.000139	0.188	CbGdCrCtD
Gefitinib—Vandetanib—VEGFA—pancreatic cancer	0.000123	0.0841	CrCbGaD
Gefitinib—CYP3A5—islet of Langerhans—pancreatic cancer	0.000117	0.0192	CbGeAlD
Gefitinib—Vandetanib—EGFR—pancreatic cancer	0.000104	0.071	CrCbGaD
Gefitinib—Bosutinib—EGFR—pancreatic cancer	9.69e-05	0.0664	CrCbGaD
Gefitinib—CYP2C19—digestive system—pancreatic cancer	8.91e-05	0.0146	CbGeAlD
Gefitinib—CYP3A5—pancreas—pancreatic cancer	8.22e-05	0.0135	CbGeAlD
Gefitinib—CYP1A1—digestive system—pancreatic cancer	7.18e-05	0.0118	CbGeAlD
Gefitinib—CYP3A5—digestive system—pancreatic cancer	7.02e-05	0.0115	CbGeAlD
Gefitinib—CYP2C9—digestive system—pancreatic cancer	6.91e-05	0.0114	CbGeAlD
Gefitinib—ABCB1—islet of Langerhans—pancreatic cancer	6.21e-05	0.0102	CbGeAlD
Gefitinib—CYP3A4—digestive system—pancreatic cancer	5.27e-05	0.00866	CbGeAlD
Gefitinib—CYP2D6—digestive system—pancreatic cancer	5.19e-05	0.00852	CbGeAlD
Gefitinib—ABCB1—pancreas—pancreatic cancer	4.37e-05	0.00718	CbGeAlD
Gefitinib—Gastrointestinal pain—Sunitinib—pancreatic cancer	3.86e-05	0.000825	CcSEcCtD
Gefitinib—Dermatitis bullous—Epirubicin—pancreatic cancer	3.86e-05	0.000825	CcSEcCtD
Gefitinib—Pruritus—Erlotinib—pancreatic cancer	3.86e-05	0.000825	CcSEcCtD
Gefitinib—Shock—Irinotecan—pancreatic cancer	3.83e-05	0.000818	CcSEcCtD
Gefitinib—Nervous system disorder—Irinotecan—pancreatic cancer	3.81e-05	0.000815	CcSEcCtD
Gefitinib—Thrombocytopenia—Irinotecan—pancreatic cancer	3.81e-05	0.000814	CcSEcCtD
Gefitinib—Haemoglobin—Docetaxel—pancreatic cancer	3.8e-05	0.000813	CcSEcCtD
Gefitinib—Hepatic failure—Doxorubicin—pancreatic cancer	3.8e-05	0.000812	CcSEcCtD
Gefitinib—Hepatitis—Docetaxel—pancreatic cancer	3.78e-05	0.000809	CcSEcCtD
Gefitinib—Haemorrhage—Docetaxel—pancreatic cancer	3.78e-05	0.000809	CcSEcCtD
Gefitinib—Eye pain—Doxorubicin—pancreatic cancer	3.78e-05	0.000808	CcSEcCtD
Gefitinib—Diarrhoea—Tamoxifen—pancreatic cancer	3.77e-05	0.000806	CcSEcCtD
Gefitinib—Infection—Gemcitabine—pancreatic cancer	3.76e-05	0.000805	CcSEcCtD
Gefitinib—Urinary tract disorder—Docetaxel—pancreatic cancer	3.74e-05	0.000799	CcSEcCtD
Gefitinib—Abdominal pain—Sunitinib—pancreatic cancer	3.73e-05	0.000798	CcSEcCtD
Gefitinib—Body temperature increased—Sunitinib—pancreatic cancer	3.73e-05	0.000798	CcSEcCtD
Gefitinib—Diarrhoea—Erlotinib—pancreatic cancer	3.73e-05	0.000798	CcSEcCtD
Gefitinib—ABCB1—digestive system—pancreatic cancer	3.73e-05	0.00613	CbGeAlD
Gefitinib—Oedema peripheral—Docetaxel—pancreatic cancer	3.73e-05	0.000797	CcSEcCtD
Gefitinib—Nervous system disorder—Gemcitabine—pancreatic cancer	3.71e-05	0.000794	CcSEcCtD
Gefitinib—Urethral disorder—Docetaxel—pancreatic cancer	3.71e-05	0.000793	CcSEcCtD
Gefitinib—Thrombocytopenia—Gemcitabine—pancreatic cancer	3.71e-05	0.000793	CcSEcCtD
Gefitinib—Anorexia—Irinotecan—pancreatic cancer	3.71e-05	0.000792	CcSEcCtD
Gefitinib—Infection—Fluorouracil—pancreatic cancer	3.7e-05	0.000791	CcSEcCtD
Gefitinib—Skin disorder—Gemcitabine—pancreatic cancer	3.68e-05	0.000787	CcSEcCtD
Gefitinib—Nervous system disorder—Fluorouracil—pancreatic cancer	3.65e-05	0.000781	CcSEcCtD
Gefitinib—Thrombocytopenia—Fluorouracil—pancreatic cancer	3.65e-05	0.00078	CcSEcCtD
Gefitinib—Hypotension—Irinotecan—pancreatic cancer	3.63e-05	0.000777	CcSEcCtD
Gefitinib—Dermatitis exfoliative—Doxorubicin—pancreatic cancer	3.62e-05	0.000773	CcSEcCtD
Gefitinib—Anorexia—Gemcitabine—pancreatic cancer	3.61e-05	0.000772	CcSEcCtD
Gefitinib—Erythema multiforme—Docetaxel—pancreatic cancer	3.58e-05	0.000765	CcSEcCtD
Gefitinib—Dermatitis bullous—Doxorubicin—pancreatic cancer	3.57e-05	0.000764	CcSEcCtD
Gefitinib—Anorexia—Fluorouracil—pancreatic cancer	3.55e-05	0.000759	CcSEcCtD
Gefitinib—Hypotension—Gemcitabine—pancreatic cancer	3.54e-05	0.000757	CcSEcCtD
Gefitinib—Eye disorder—Docetaxel—pancreatic cancer	3.54e-05	0.000756	CcSEcCtD
Gefitinib—Cardiac disorder—Docetaxel—pancreatic cancer	3.51e-05	0.000751	CcSEcCtD
Gefitinib—Vomiting—Tamoxifen—pancreatic cancer	3.5e-05	0.000749	CcSEcCtD
Gefitinib—Hypotension—Fluorouracil—pancreatic cancer	3.48e-05	0.000744	CcSEcCtD
Gefitinib—Hypersensitivity—Sunitinib—pancreatic cancer	3.48e-05	0.000744	CcSEcCtD
Gefitinib—Rash—Tamoxifen—pancreatic cancer	3.48e-05	0.000743	CcSEcCtD
Gefitinib—Dermatitis—Tamoxifen—pancreatic cancer	3.47e-05	0.000742	CcSEcCtD
Gefitinib—Vomiting—Erlotinib—pancreatic cancer	3.47e-05	0.000741	CcSEcCtD
Gefitinib—Dyspnoea—Irinotecan—pancreatic cancer	3.47e-05	0.000741	CcSEcCtD
Gefitinib—Rash—Erlotinib—pancreatic cancer	3.44e-05	0.000735	CcSEcCtD
Gefitinib—Dermatitis—Erlotinib—pancreatic cancer	3.44e-05	0.000734	CcSEcCtD
Gefitinib—Angiopathy—Docetaxel—pancreatic cancer	3.43e-05	0.000734	CcSEcCtD
Gefitinib—Dehydration—Epirubicin—pancreatic cancer	3.43e-05	0.000733	CcSEcCtD
Gefitinib—Mediastinal disorder—Docetaxel—pancreatic cancer	3.41e-05	0.000729	CcSEcCtD
Gefitinib—Asthenia—Sunitinib—pancreatic cancer	3.39e-05	0.000724	CcSEcCtD
Gefitinib—Dry skin—Epirubicin—pancreatic cancer	3.38e-05	0.000723	CcSEcCtD
Gefitinib—Decreased appetite—Irinotecan—pancreatic cancer	3.38e-05	0.000723	CcSEcCtD
Gefitinib—Arrhythmia—Docetaxel—pancreatic cancer	3.38e-05	0.000723	CcSEcCtD
Gefitinib—Dyspnoea—Gemcitabine—pancreatic cancer	3.38e-05	0.000722	CcSEcCtD
Gefitinib—Hypokalaemia—Epirubicin—pancreatic cancer	3.36e-05	0.000718	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Irinotecan—pancreatic cancer	3.36e-05	0.000718	CcSEcCtD
Gefitinib—Fatigue—Irinotecan—pancreatic cancer	3.35e-05	0.000717	CcSEcCtD
Gefitinib—Alopecia—Docetaxel—pancreatic cancer	3.34e-05	0.000715	CcSEcCtD
Gefitinib—Pruritus—Sunitinib—pancreatic cancer	3.34e-05	0.000714	CcSEcCtD
Gefitinib—Constipation—Irinotecan—pancreatic cancer	3.33e-05	0.000711	CcSEcCtD
Gefitinib—Pain—Irinotecan—pancreatic cancer	3.33e-05	0.000711	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Epirubicin—pancreatic cancer	3.32e-05	0.00071	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	3.32e-05	0.00071	CcSEcCtD
Gefitinib—Dyspnoea—Fluorouracil—pancreatic cancer	3.32e-05	0.00071	CcSEcCtD
Gefitinib—Malnutrition—Docetaxel—pancreatic cancer	3.29e-05	0.000704	CcSEcCtD
Gefitinib—Decreased appetite—Gemcitabine—pancreatic cancer	3.29e-05	0.000704	CcSEcCtD
Gefitinib—Nausea—Tamoxifen—pancreatic cancer	3.27e-05	0.0007	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	3.27e-05	0.000699	CcSEcCtD
Gefitinib—Fatigue—Gemcitabine—pancreatic cancer	3.27e-05	0.000698	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	3.25e-05	0.000696	CcSEcCtD
Gefitinib—Pain—Gemcitabine—pancreatic cancer	3.24e-05	0.000693	CcSEcCtD
Gefitinib—Constipation—Gemcitabine—pancreatic cancer	3.24e-05	0.000693	CcSEcCtD
Gefitinib—Nausea—Erlotinib—pancreatic cancer	3.24e-05	0.000693	CcSEcCtD
Gefitinib—Decreased appetite—Fluorouracil—pancreatic cancer	3.24e-05	0.000692	CcSEcCtD
Gefitinib—Diarrhoea—Sunitinib—pancreatic cancer	3.23e-05	0.000691	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	3.22e-05	0.000687	CcSEcCtD
Gefitinib—Pain—Fluorouracil—pancreatic cancer	3.18e-05	0.000681	CcSEcCtD
Gefitinib—Gastrointestinal pain—Irinotecan—pancreatic cancer	3.18e-05	0.00068	CcSEcCtD
Gefitinib—Dehydration—Doxorubicin—pancreatic cancer	3.17e-05	0.000679	CcSEcCtD
Gefitinib—Dry skin—Doxorubicin—pancreatic cancer	3.13e-05	0.000669	CcSEcCtD
Gefitinib—Pancreatitis—Epirubicin—pancreatic cancer	3.13e-05	0.000668	CcSEcCtD
Gefitinib—Hypokalaemia—Doxorubicin—pancreatic cancer	3.11e-05	0.000664	CcSEcCtD
Gefitinib—Body temperature increased—Irinotecan—pancreatic cancer	3.07e-05	0.000657	CcSEcCtD
Gefitinib—Abdominal pain—Irinotecan—pancreatic cancer	3.07e-05	0.000657	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	3.07e-05	0.000657	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	3.07e-05	0.000657	CcSEcCtD
Gefitinib—Anaemia—Docetaxel—pancreatic cancer	3.04e-05	0.000651	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	3.01e-05	0.000644	CcSEcCtD
Gefitinib—Vomiting—Sunitinib—pancreatic cancer	3e-05	0.000642	CcSEcCtD
Gefitinib—Body temperature increased—Gemcitabine—pancreatic cancer	2.99e-05	0.00064	CcSEcCtD
Gefitinib—Rash—Sunitinib—pancreatic cancer	2.98e-05	0.000636	CcSEcCtD
Gefitinib—Dermatitis—Sunitinib—pancreatic cancer	2.97e-05	0.000636	CcSEcCtD
Gefitinib—Urticaria—Fluorouracil—pancreatic cancer	2.96e-05	0.000633	CcSEcCtD
Gefitinib—Body temperature increased—Fluorouracil—pancreatic cancer	2.94e-05	0.000629	CcSEcCtD
Gefitinib—Pancreatitis—Doxorubicin—pancreatic cancer	2.89e-05	0.000618	CcSEcCtD
Gefitinib—Weight decreased—Epirubicin—pancreatic cancer	2.88e-05	0.000617	CcSEcCtD
Gefitinib—Cough—Docetaxel—pancreatic cancer	2.87e-05	0.000614	CcSEcCtD
Gefitinib—Hypersensitivity—Irinotecan—pancreatic cancer	2.86e-05	0.000613	CcSEcCtD
Gefitinib—Pneumonia—Epirubicin—pancreatic cancer	2.86e-05	0.000611	CcSEcCtD
Gefitinib—Infestation NOS—Epirubicin—pancreatic cancer	2.84e-05	0.000608	CcSEcCtD
Gefitinib—Infestation—Epirubicin—pancreatic cancer	2.84e-05	0.000608	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	2.82e-05	0.000603	CcSEcCtD
Gefitinib—Nausea—Sunitinib—pancreatic cancer	2.8e-05	0.0006	CcSEcCtD
Gefitinib—Asthenia—Irinotecan—pancreatic cancer	2.79e-05	0.000596	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	2.78e-05	0.000595	CcSEcCtD
Gefitinib—Stomatitis—Epirubicin—pancreatic cancer	2.77e-05	0.000592	CcSEcCtD
Gefitinib—Conjunctivitis—Epirubicin—pancreatic cancer	2.76e-05	0.000591	CcSEcCtD
Gefitinib—Hypersensitivity—Fluorouracil—pancreatic cancer	2.74e-05	0.000587	CcSEcCtD
Gefitinib—Dry mouth—Docetaxel—pancreatic cancer	2.74e-05	0.000586	CcSEcCtD
Gefitinib—Asthenia—Gemcitabine—pancreatic cancer	2.72e-05	0.000581	CcSEcCtD
Gefitinib—Haematuria—Epirubicin—pancreatic cancer	2.71e-05	0.00058	CcSEcCtD
Gefitinib—Hepatobiliary disease—Epirubicin—pancreatic cancer	2.69e-05	0.000575	CcSEcCtD
Gefitinib—Epistaxis—Epirubicin—pancreatic cancer	2.68e-05	0.000573	CcSEcCtD
Gefitinib—Pruritus—Gemcitabine—pancreatic cancer	2.68e-05	0.000573	CcSEcCtD
Gefitinib—Infection—Docetaxel—pancreatic cancer	2.67e-05	0.000571	CcSEcCtD
Gefitinib—Weight decreased—Doxorubicin—pancreatic cancer	2.67e-05	0.000571	CcSEcCtD
Gefitinib—Diarrhoea—Irinotecan—pancreatic cancer	2.66e-05	0.000569	CcSEcCtD
Gefitinib—Pneumonia—Doxorubicin—pancreatic cancer	2.65e-05	0.000566	CcSEcCtD
Gefitinib—Shock—Docetaxel—pancreatic cancer	2.64e-05	0.000565	CcSEcCtD
Gefitinib—Nervous system disorder—Docetaxel—pancreatic cancer	2.64e-05	0.000564	CcSEcCtD
Gefitinib—Pruritus—Fluorouracil—pancreatic cancer	2.63e-05	0.000563	CcSEcCtD
Gefitinib—Thrombocytopenia—Docetaxel—pancreatic cancer	2.63e-05	0.000563	CcSEcCtD
Gefitinib—Infestation NOS—Doxorubicin—pancreatic cancer	2.63e-05	0.000562	CcSEcCtD
Gefitinib—Infestation—Doxorubicin—pancreatic cancer	2.63e-05	0.000562	CcSEcCtD
Gefitinib—Skin disorder—Docetaxel—pancreatic cancer	2.61e-05	0.000558	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	2.61e-05	0.000558	CcSEcCtD
Gefitinib—Diarrhoea—Gemcitabine—pancreatic cancer	2.59e-05	0.000554	CcSEcCtD
Gefitinib—Haemoglobin—Epirubicin—pancreatic cancer	2.56e-05	0.000548	CcSEcCtD
Gefitinib—Stomatitis—Doxorubicin—pancreatic cancer	2.56e-05	0.000548	CcSEcCtD
Gefitinib—Anorexia—Docetaxel—pancreatic cancer	2.56e-05	0.000548	CcSEcCtD
Gefitinib—Conjunctivitis—Doxorubicin—pancreatic cancer	2.56e-05	0.000547	CcSEcCtD
Gefitinib—Hepatitis—Epirubicin—pancreatic cancer	2.55e-05	0.000546	CcSEcCtD
Gefitinib—Haemorrhage—Epirubicin—pancreatic cancer	2.55e-05	0.000546	CcSEcCtD
Gefitinib—Diarrhoea—Fluorouracil—pancreatic cancer	2.55e-05	0.000545	CcSEcCtD
Gefitinib—Urinary tract disorder—Epirubicin—pancreatic cancer	2.52e-05	0.000539	CcSEcCtD
Gefitinib—Oedema peripheral—Epirubicin—pancreatic cancer	2.51e-05	0.000537	CcSEcCtD
Gefitinib—Hypotension—Docetaxel—pancreatic cancer	2.51e-05	0.000537	CcSEcCtD
Gefitinib—Haematuria—Doxorubicin—pancreatic cancer	2.51e-05	0.000536	CcSEcCtD
Gefitinib—Urethral disorder—Epirubicin—pancreatic cancer	2.5e-05	0.000535	CcSEcCtD
Gefitinib—Hepatobiliary disease—Doxorubicin—pancreatic cancer	2.49e-05	0.000532	CcSEcCtD
Gefitinib—Epistaxis—Doxorubicin—pancreatic cancer	2.48e-05	0.00053	CcSEcCtD
Gefitinib—Vomiting—Irinotecan—pancreatic cancer	2.47e-05	0.000529	CcSEcCtD
Gefitinib—Rash—Irinotecan—pancreatic cancer	2.45e-05	0.000524	CcSEcCtD
Gefitinib—Dermatitis—Irinotecan—pancreatic cancer	2.45e-05	0.000524	CcSEcCtD
Gefitinib—Erythema multiforme—Epirubicin—pancreatic cancer	2.41e-05	0.000516	CcSEcCtD
Gefitinib—Vomiting—Gemcitabine—pancreatic cancer	2.41e-05	0.000515	CcSEcCtD
Gefitinib—Dyspnoea—Docetaxel—pancreatic cancer	2.4e-05	0.000512	CcSEcCtD
Gefitinib—Rash—Gemcitabine—pancreatic cancer	2.39e-05	0.000511	CcSEcCtD
Gefitinib—Dermatitis—Gemcitabine—pancreatic cancer	2.39e-05	0.00051	CcSEcCtD
Gefitinib—Eye disorder—Epirubicin—pancreatic cancer	2.38e-05	0.00051	CcSEcCtD
Gefitinib—Haemoglobin—Doxorubicin—pancreatic cancer	2.37e-05	0.000507	CcSEcCtD
Gefitinib—Cardiac disorder—Epirubicin—pancreatic cancer	2.37e-05	0.000506	CcSEcCtD
Gefitinib—Vomiting—Fluorouracil—pancreatic cancer	2.37e-05	0.000506	CcSEcCtD
Gefitinib—Haemorrhage—Doxorubicin—pancreatic cancer	2.36e-05	0.000505	CcSEcCtD
Gefitinib—Hepatitis—Doxorubicin—pancreatic cancer	2.36e-05	0.000505	CcSEcCtD
Gefitinib—Rash—Fluorouracil—pancreatic cancer	2.35e-05	0.000502	CcSEcCtD
Gefitinib—Dermatitis—Fluorouracil—pancreatic cancer	2.35e-05	0.000502	CcSEcCtD
Gefitinib—Decreased appetite—Docetaxel—pancreatic cancer	2.34e-05	0.0005	CcSEcCtD
Gefitinib—Urinary tract disorder—Doxorubicin—pancreatic cancer	2.33e-05	0.000499	CcSEcCtD
Gefitinib—Oedema peripheral—Doxorubicin—pancreatic cancer	2.33e-05	0.000497	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Docetaxel—pancreatic cancer	2.32e-05	0.000496	CcSEcCtD
Gefitinib—Fatigue—Docetaxel—pancreatic cancer	2.32e-05	0.000495	CcSEcCtD
Gefitinib—Angiopathy—Epirubicin—pancreatic cancer	2.32e-05	0.000495	CcSEcCtD
Gefitinib—Urethral disorder—Doxorubicin—pancreatic cancer	2.31e-05	0.000495	CcSEcCtD
Gefitinib—Nausea—Irinotecan—pancreatic cancer	2.31e-05	0.000494	CcSEcCtD
Gefitinib—Mediastinal disorder—Epirubicin—pancreatic cancer	2.3e-05	0.000492	CcSEcCtD
Gefitinib—Pain—Docetaxel—pancreatic cancer	2.3e-05	0.000491	CcSEcCtD
Gefitinib—Constipation—Docetaxel—pancreatic cancer	2.3e-05	0.000491	CcSEcCtD
Gefitinib—Arrhythmia—Epirubicin—pancreatic cancer	2.28e-05	0.000487	CcSEcCtD
Gefitinib—Alopecia—Epirubicin—pancreatic cancer	2.26e-05	0.000482	CcSEcCtD
Gefitinib—Nausea—Gemcitabine—pancreatic cancer	2.25e-05	0.000481	CcSEcCtD
Gefitinib—Erythema multiforme—Doxorubicin—pancreatic cancer	2.23e-05	0.000477	CcSEcCtD
Gefitinib—Malnutrition—Epirubicin—pancreatic cancer	2.22e-05	0.000475	CcSEcCtD
Gefitinib—Nausea—Fluorouracil—pancreatic cancer	2.21e-05	0.000473	CcSEcCtD
Gefitinib—Eye disorder—Doxorubicin—pancreatic cancer	2.21e-05	0.000472	CcSEcCtD
Gefitinib—Gastrointestinal pain—Docetaxel—pancreatic cancer	2.2e-05	0.00047	CcSEcCtD
Gefitinib—Cardiac disorder—Doxorubicin—pancreatic cancer	2.19e-05	0.000469	CcSEcCtD
Gefitinib—Angiopathy—Doxorubicin—pancreatic cancer	2.14e-05	0.000458	CcSEcCtD
Gefitinib—Mediastinal disorder—Doxorubicin—pancreatic cancer	2.13e-05	0.000455	CcSEcCtD
Gefitinib—Abdominal pain—Docetaxel—pancreatic cancer	2.12e-05	0.000454	CcSEcCtD
Gefitinib—Body temperature increased—Docetaxel—pancreatic cancer	2.12e-05	0.000454	CcSEcCtD
Gefitinib—Arrhythmia—Doxorubicin—pancreatic cancer	2.11e-05	0.000451	CcSEcCtD
Gefitinib—Alopecia—Doxorubicin—pancreatic cancer	2.09e-05	0.000446	CcSEcCtD
Gefitinib—Malnutrition—Doxorubicin—pancreatic cancer	2.06e-05	0.000439	CcSEcCtD
Gefitinib—Anaemia—Epirubicin—pancreatic cancer	2.05e-05	0.000439	CcSEcCtD
Gefitinib—Malaise—Epirubicin—pancreatic cancer	2e-05	0.000428	CcSEcCtD
Gefitinib—Hypersensitivity—Docetaxel—pancreatic cancer	1.98e-05	0.000423	CcSEcCtD
Gefitinib—Cough—Epirubicin—pancreatic cancer	1.94e-05	0.000414	CcSEcCtD
Gefitinib—Asthenia—Docetaxel—pancreatic cancer	1.93e-05	0.000412	CcSEcCtD
Gefitinib—Pruritus—Docetaxel—pancreatic cancer	1.9e-05	0.000407	CcSEcCtD
Gefitinib—Anaemia—Doxorubicin—pancreatic cancer	1.9e-05	0.000406	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	1.88e-05	0.000402	CcSEcCtD
Gefitinib—Malaise—Doxorubicin—pancreatic cancer	1.85e-05	0.000396	CcSEcCtD
Gefitinib—Dry mouth—Epirubicin—pancreatic cancer	1.85e-05	0.000395	CcSEcCtD
Gefitinib—Diarrhoea—Docetaxel—pancreatic cancer	1.84e-05	0.000393	CcSEcCtD
Gefitinib—Infection—Epirubicin—pancreatic cancer	1.8e-05	0.000385	CcSEcCtD
Gefitinib—Cough—Doxorubicin—pancreatic cancer	1.79e-05	0.000383	CcSEcCtD
Gefitinib—Shock—Epirubicin—pancreatic cancer	1.78e-05	0.000381	CcSEcCtD
Gefitinib—Nervous system disorder—Epirubicin—pancreatic cancer	1.78e-05	0.00038	CcSEcCtD
Gefitinib—Thrombocytopenia—Epirubicin—pancreatic cancer	1.78e-05	0.00038	CcSEcCtD
Gefitinib—Skin disorder—Epirubicin—pancreatic cancer	1.76e-05	0.000377	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	1.74e-05	0.000372	CcSEcCtD
Gefitinib—Anorexia—Epirubicin—pancreatic cancer	1.73e-05	0.00037	CcSEcCtD
Gefitinib—Dry mouth—Doxorubicin—pancreatic cancer	1.71e-05	0.000366	CcSEcCtD
Gefitinib—Vomiting—Docetaxel—pancreatic cancer	1.71e-05	0.000365	CcSEcCtD
Gefitinib—Rash—Docetaxel—pancreatic cancer	1.69e-05	0.000362	CcSEcCtD
Gefitinib—Hypotension—Epirubicin—pancreatic cancer	1.69e-05	0.000362	CcSEcCtD
Gefitinib—Dermatitis—Docetaxel—pancreatic cancer	1.69e-05	0.000362	CcSEcCtD
Gefitinib—Infection—Doxorubicin—pancreatic cancer	1.67e-05	0.000356	CcSEcCtD
Gefitinib—Shock—Doxorubicin—pancreatic cancer	1.65e-05	0.000353	CcSEcCtD
Gefitinib—Nervous system disorder—Doxorubicin—pancreatic cancer	1.65e-05	0.000352	CcSEcCtD
Gefitinib—Thrombocytopenia—Doxorubicin—pancreatic cancer	1.64e-05	0.000351	CcSEcCtD
Gefitinib—Skin disorder—Doxorubicin—pancreatic cancer	1.63e-05	0.000348	CcSEcCtD
Gefitinib—Dyspnoea—Epirubicin—pancreatic cancer	1.62e-05	0.000346	CcSEcCtD
Gefitinib—Anorexia—Doxorubicin—pancreatic cancer	1.6e-05	0.000342	CcSEcCtD
Gefitinib—Nausea—Docetaxel—pancreatic cancer	1.6e-05	0.000341	CcSEcCtD
Gefitinib—Decreased appetite—Epirubicin—pancreatic cancer	1.58e-05	0.000337	CcSEcCtD
Gefitinib—Hypotension—Doxorubicin—pancreatic cancer	1.57e-05	0.000335	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Epirubicin—pancreatic cancer	1.57e-05	0.000335	CcSEcCtD
Gefitinib—Fatigue—Epirubicin—pancreatic cancer	1.56e-05	0.000334	CcSEcCtD
Gefitinib—Pain—Epirubicin—pancreatic cancer	1.55e-05	0.000331	CcSEcCtD
Gefitinib—Constipation—Epirubicin—pancreatic cancer	1.55e-05	0.000331	CcSEcCtD
Gefitinib—Dyspnoea—Doxorubicin—pancreatic cancer	1.5e-05	0.00032	CcSEcCtD
Gefitinib—Gastrointestinal pain—Epirubicin—pancreatic cancer	1.48e-05	0.000317	CcSEcCtD
Gefitinib—Decreased appetite—Doxorubicin—pancreatic cancer	1.46e-05	0.000312	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	1.45e-05	0.00031	CcSEcCtD
Gefitinib—Fatigue—Doxorubicin—pancreatic cancer	1.45e-05	0.000309	CcSEcCtD
Gefitinib—Urticaria—Epirubicin—pancreatic cancer	1.44e-05	0.000308	CcSEcCtD
Gefitinib—Pain—Doxorubicin—pancreatic cancer	1.43e-05	0.000307	CcSEcCtD
Gefitinib—Constipation—Doxorubicin—pancreatic cancer	1.43e-05	0.000307	CcSEcCtD
Gefitinib—Abdominal pain—Epirubicin—pancreatic cancer	1.43e-05	0.000306	CcSEcCtD
Gefitinib—Body temperature increased—Epirubicin—pancreatic cancer	1.43e-05	0.000306	CcSEcCtD
Gefitinib—Gastrointestinal pain—Doxorubicin—pancreatic cancer	1.37e-05	0.000293	CcSEcCtD
Gefitinib—Hypersensitivity—Epirubicin—pancreatic cancer	1.34e-05	0.000286	CcSEcCtD
Gefitinib—Urticaria—Doxorubicin—pancreatic cancer	1.33e-05	0.000285	CcSEcCtD
Gefitinib—Abdominal pain—Doxorubicin—pancreatic cancer	1.33e-05	0.000284	CcSEcCtD
Gefitinib—Body temperature increased—Doxorubicin—pancreatic cancer	1.33e-05	0.000284	CcSEcCtD
Gefitinib—Asthenia—Epirubicin—pancreatic cancer	1.3e-05	0.000278	CcSEcCtD
Gefitinib—Pruritus—Epirubicin—pancreatic cancer	1.28e-05	0.000274	CcSEcCtD
Gefitinib—Diarrhoea—Epirubicin—pancreatic cancer	1.24e-05	0.000265	CcSEcCtD
Gefitinib—Hypersensitivity—Doxorubicin—pancreatic cancer	1.24e-05	0.000264	CcSEcCtD
Gefitinib—Asthenia—Doxorubicin—pancreatic cancer	1.2e-05	0.000257	CcSEcCtD
Gefitinib—Pruritus—Doxorubicin—pancreatic cancer	1.19e-05	0.000254	CcSEcCtD
Gefitinib—Vomiting—Epirubicin—pancreatic cancer	1.15e-05	0.000246	CcSEcCtD
Gefitinib—Diarrhoea—Doxorubicin—pancreatic cancer	1.15e-05	0.000245	CcSEcCtD
Gefitinib—Rash—Epirubicin—pancreatic cancer	1.14e-05	0.000244	CcSEcCtD
Gefitinib—Dermatitis—Epirubicin—pancreatic cancer	1.14e-05	0.000244	CcSEcCtD
Gefitinib—Nausea—Epirubicin—pancreatic cancer	1.08e-05	0.00023	CcSEcCtD
Gefitinib—Vomiting—Doxorubicin—pancreatic cancer	1.07e-05	0.000228	CcSEcCtD
Gefitinib—Rash—Doxorubicin—pancreatic cancer	1.06e-05	0.000226	CcSEcCtD
Gefitinib—Dermatitis—Doxorubicin—pancreatic cancer	1.06e-05	0.000226	CcSEcCtD
Gefitinib—Nausea—Doxorubicin—pancreatic cancer	9.96e-06	0.000213	CcSEcCtD
Gefitinib—ERBB3—Signaling Pathways—PTEN—pancreatic cancer	1.35e-06	3.74e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TERT—pancreatic cancer	1.34e-06	3.74e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.34e-06	3.73e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PIK3CB—pancreatic cancer	1.34e-06	3.73e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—KRAS—pancreatic cancer	1.33e-06	3.7e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.33e-06	3.7e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GCG—pancreatic cancer	1.31e-06	3.65e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—AKT1—pancreatic cancer	1.31e-06	3.64e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—HRAS—pancreatic cancer	1.3e-06	3.61e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—AKT1—pancreatic cancer	1.3e-06	3.61e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PIK3CB—pancreatic cancer	1.3e-06	3.61e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—SRC—pancreatic cancer	1.3e-06	3.6e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HIF1A—pancreatic cancer	1.29e-06	3.57e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TSC2—pancreatic cancer	1.28e-06	3.56e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.27e-06	3.54e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TYMP—pancreatic cancer	1.27e-06	3.53e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CG—pancreatic cancer	1.26e-06	3.51e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—VEGFA—pancreatic cancer	1.26e-06	3.51e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.26e-06	3.5e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—HRAS—pancreatic cancer	1.26e-06	3.49e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—APOE—pancreatic cancer	1.26e-06	3.49e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—STAT3—pancreatic cancer	1.25e-06	3.47e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—SRC—pancreatic cancer	1.25e-06	3.47e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HRAS—pancreatic cancer	1.25e-06	3.47e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—PIK3CA—pancreatic cancer	1.25e-06	3.47e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CXCL8—pancreatic cancer	1.25e-06	3.47e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—NRAS—pancreatic cancer	1.25e-06	3.47e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PIK3CB—pancreatic cancer	1.24e-06	3.44e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—STK11—pancreatic cancer	1.24e-06	3.44e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—TYMS—pancreatic cancer	1.23e-06	3.43e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CD44—pancreatic cancer	1.23e-06	3.42e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KDR—pancreatic cancer	1.23e-06	3.42e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTGS2—pancreatic cancer	1.23e-06	3.41e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—PIK3CA—pancreatic cancer	1.22e-06	3.4e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PPARG—pancreatic cancer	1.22e-06	3.39e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—VEGFA—pancreatic cancer	1.22e-06	3.38e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TP53—pancreatic cancer	1.21e-06	3.35e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.21e-06	3.35e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—STAT3—pancreatic cancer	1.21e-06	3.35e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—NRAS—pancreatic cancer	1.2e-06	3.34e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CD44—pancreatic cancer	1.2e-06	3.34e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—AKT1—pancreatic cancer	1.2e-06	3.34e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.19e-06	3.32e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CASP3—pancreatic cancer	1.19e-06	3.32e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CTNNB1—pancreatic cancer	1.19e-06	3.31e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—SRC—pancreatic cancer	1.18e-06	3.28e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GCG—pancreatic cancer	1.18e-06	3.28e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NFKBIA—pancreatic cancer	1.17e-06	3.25e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—TYMS—pancreatic cancer	1.17e-06	3.24e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCND1—pancreatic cancer	1.16e-06	3.23e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MYC—pancreatic cancer	1.16e-06	3.23e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.16e-06	3.22e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PTEN—pancreatic cancer	1.16e-06	3.22e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TGFB1—pancreatic cancer	1.16e-06	3.22e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NOTCH1—pancreatic cancer	1.16e-06	3.22e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—HRAS—pancreatic cancer	1.15e-06	3.21e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GCG—pancreatic cancer	1.15e-06	3.2e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—VEGFA—pancreatic cancer	1.15e-06	3.2e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CTNNB1—pancreatic cancer	1.15e-06	3.2e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—AKT1—pancreatic cancer	1.15e-06	3.19e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—NRAS—pancreatic cancer	1.14e-06	3.16e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—EGFR—pancreatic cancer	1.14e-06	3.16e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CG—pancreatic cancer	1.13e-06	3.15e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—NRAS—pancreatic cancer	1.13e-06	3.15e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HRAS—pancreatic cancer	1.13e-06	3.15e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CD44—pancreatic cancer	1.13e-06	3.15e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MMP9—pancreatic cancer	1.13e-06	3.14e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CD44—pancreatic cancer	1.12e-06	3.12e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PTEN—pancreatic cancer	1.12e-06	3.12e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—EGF—pancreatic cancer	1.12e-06	3.11e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MYC—pancreatic cancer	1.12e-06	3.11e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TGFB1—pancreatic cancer	1.12e-06	3.1e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CD—pancreatic cancer	1.11e-06	3.09e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—STK11—pancreatic cancer	1.11e-06	3.08e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—AKT1—pancreatic cancer	1.11e-06	3.08e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—AKT1—pancreatic cancer	1.1e-06	3.06e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.1e-06	3.05e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CTNNB1—pancreatic cancer	1.1e-06	3.05e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EGFR—pancreatic cancer	1.1e-06	3.04e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.09e-06	3.03e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GCG—pancreatic cancer	1.09e-06	3.02e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—STK11—pancreatic cancer	1.08e-06	3.01e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GCG—pancreatic cancer	1.08e-06	2.99e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—SRC—pancreatic cancer	1.08e-06	2.99e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—KRAS—pancreatic cancer	1.07e-06	2.98e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTEN—pancreatic cancer	1.07e-06	2.98e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—TYMS—pancreatic cancer	1.06e-06	2.95e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TGFB1—pancreatic cancer	1.06e-06	2.94e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.04e-06	2.89e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—SRC—pancreatic cancer	1.04e-06	2.89e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—STAT3—pancreatic cancer	1.04e-06	2.88e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—NRAS—pancreatic cancer	1.04e-06	2.88e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—KRAS—pancreatic cancer	1.03e-06	2.88e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GLP1R—pancreatic cancer	1.02e-06	2.85e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—STK11—pancreatic cancer	1.02e-06	2.84e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—AKT1—pancreatic cancer	1.02e-06	2.83e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—VEGFA—pancreatic cancer	1.01e-06	2.82e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—STK11—pancreatic cancer	1.01e-06	2.81e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—DPYD—pancreatic cancer	1.01e-06	2.8e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—APOE—pancreatic cancer	1e-06	2.79e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—STAT3—pancreatic cancer	1e-06	2.79e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NRAS—pancreatic cancer	1e-06	2.78e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—AKT1—pancreatic cancer	1e-06	2.78e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CD—pancreatic cancer	9.96e-07	2.77e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—SRC—pancreatic cancer	9.93e-07	2.76e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PIK3CA—pancreatic cancer	9.86e-07	2.74e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—KRAS—pancreatic cancer	9.79e-07	2.72e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—KRAS—pancreatic cancer	9.75e-07	2.71e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CB—pancreatic cancer	9.69e-07	2.69e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTGS2—pancreatic cancer	9.6e-07	2.67e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—STAT3—pancreatic cancer	9.58e-07	2.66e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	9.56e-07	2.66e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—NRAS—pancreatic cancer	9.56e-07	2.66e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—TYMS—pancreatic cancer	9.55e-07	2.65e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—pancreatic cancer	9.54e-07	2.65e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PIK3CA—pancreatic cancer	9.51e-07	2.64e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	9.5e-07	2.64e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—APOE—pancreatic cancer	9.49e-07	2.64e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MYC—pancreatic cancer	9.32e-07	2.59e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—TYMS—pancreatic cancer	9.32e-07	2.59e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TGFB1—pancreatic cancer	9.3e-07	2.58e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—pancreatic cancer	9.2e-07	2.56e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—HRAS—pancreatic cancer	9.12e-07	2.54e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EGFR—pancreatic cancer	9.12e-07	2.53e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CG—pancreatic cancer	9.06e-07	2.52e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—PIK3CA—pancreatic cancer	8.99e-07	2.5e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	8.98e-07	2.5e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—PIK3CA—pancreatic cancer	8.96e-07	2.49e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—KRAS—pancreatic cancer	8.91e-07	2.48e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MYC—pancreatic cancer	8.9e-07	2.47e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—TGFB1—pancreatic cancer	8.88e-07	2.47e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—HRAS—pancreatic cancer	8.8e-07	2.44e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—TYMS—pancreatic cancer	8.78e-07	2.44e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PPARG—pancreatic cancer	8.75e-07	2.43e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—TYMS—pancreatic cancer	8.7e-07	2.42e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—pancreatic cancer	8.7e-07	2.42e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CB—pancreatic cancer	8.68e-07	2.41e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—APOE—pancreatic cancer	8.65e-07	2.4e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—KRAS—pancreatic cancer	8.61e-07	2.39e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CG—pancreatic cancer	8.56e-07	2.38e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTEN—pancreatic cancer	8.38e-07	2.33e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CXCL8—pancreatic cancer	8.34e-07	2.32e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—HRAS—pancreatic cancer	8.32e-07	2.31e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—HRAS—pancreatic cancer	8.29e-07	2.3e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PPARG—pancreatic cancer	8.26e-07	2.3e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—KRAS—pancreatic cancer	8.23e-07	2.29e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	8.19e-07	2.27e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PIK3CA—pancreatic cancer	8.19e-07	2.27e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—AKT1—pancreatic cancer	8.06e-07	2.24e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CASP3—pancreatic cancer	7.99e-07	2.22e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CD—pancreatic cancer	7.97e-07	2.21e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PIK3CA—pancreatic cancer	7.91e-07	2.2e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CG—pancreatic cancer	7.81e-07	2.17e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCND1—pancreatic cancer	7.77e-07	2.16e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—AKT1—pancreatic cancer	7.77e-07	2.16e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—APOE—pancreatic cancer	7.76e-07	2.16e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CTNNB1—pancreatic cancer	7.7e-07	2.14e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—pancreatic cancer	7.66e-07	2.13e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—APOE—pancreatic cancer	7.58e-07	2.11e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HRAS—pancreatic cancer	7.57e-07	2.1e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PIK3CA—pancreatic cancer	7.56e-07	2.1e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MMP9—pancreatic cancer	7.55e-07	2.1e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PPARG—pancreatic cancer	7.53e-07	2.09e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CD—pancreatic cancer	7.53e-07	2.09e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PTEN—pancreatic cancer	7.5e-07	2.08e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CD44—pancreatic cancer	7.4e-07	2.06e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	7.35e-07	2.04e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—AKT1—pancreatic cancer	7.35e-07	2.04e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—HRAS—pancreatic cancer	7.32e-07	2.03e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—AKT1—pancreatic cancer	7.32e-07	2.03e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—APOE—pancreatic cancer	7.14e-07	1.98e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GCG—pancreatic cancer	7.1e-07	1.97e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—APOE—pancreatic cancer	7.08e-07	1.97e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	7.01e-07	1.95e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—HRAS—pancreatic cancer	6.99e-07	1.94e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SRC—pancreatic cancer	6.96e-07	1.93e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	6.94e-07	1.93e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTGS2—pancreatic cancer	6.88e-07	1.91e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CD—pancreatic cancer	6.86e-07	1.91e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CG—pancreatic cancer	6.84e-07	1.9e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VEGFA—pancreatic cancer	6.78e-07	1.88e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PPARG—pancreatic cancer	6.76e-07	1.88e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—STAT3—pancreatic cancer	6.71e-07	1.86e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	6.7e-07	1.86e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NRAS—pancreatic cancer	6.69e-07	1.86e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—AKT1—pancreatic cancer	6.69e-07	1.86e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—STK11—pancreatic cancer	6.67e-07	1.85e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PPARG—pancreatic cancer	6.6e-07	1.83e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CB—pancreatic cancer	6.56e-07	1.82e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTGS2—pancreatic cancer	6.5e-07	1.81e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—AKT1—pancreatic cancer	6.47e-07	1.8e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	6.44e-07	1.79e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	6.39e-07	1.78e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MYC—pancreatic cancer	6.23e-07	1.73e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PPARG—pancreatic cancer	6.22e-07	1.73e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TGFB1—pancreatic cancer	6.22e-07	1.73e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—AKT1—pancreatic cancer	6.17e-07	1.72e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PPARG—pancreatic cancer	6.17e-07	1.71e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	6.16e-07	1.71e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CD—pancreatic cancer	6.01e-07	1.67e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTEN—pancreatic cancer	6e-07	1.67e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CB—pancreatic cancer	5.98e-07	1.66e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTGS2—pancreatic cancer	5.93e-07	1.65e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CA—pancreatic cancer	5.91e-07	1.64e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KRAS—pancreatic cancer	5.76e-07	1.6e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TYMS—pancreatic cancer	5.74e-07	1.6e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTEN—pancreatic cancer	5.67e-07	1.58e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	5.67e-07	1.57e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	5.62e-07	1.56e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	5.37e-07	1.49e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTGS2—pancreatic cancer	5.32e-07	1.48e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CA—pancreatic cancer	5.29e-07	1.47e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CB—pancreatic cancer	5.24e-07	1.46e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTGS2—pancreatic cancer	5.19e-07	1.44e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTEN—pancreatic cancer	5.17e-07	1.44e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—pancreatic cancer	5.12e-07	1.42e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	4.94e-07	1.37e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HRAS—pancreatic cancer	4.9e-07	1.36e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	4.9e-07	1.36e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTGS2—pancreatic cancer	4.89e-07	1.36e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTGS2—pancreatic cancer	4.85e-07	1.35e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—AKT1—pancreatic cancer	4.83e-07	1.34e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—APOE—pancreatic cancer	4.67e-07	1.3e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTEN—pancreatic cancer	4.64e-07	1.29e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTEN—pancreatic cancer	4.53e-07	1.26e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AKT1—pancreatic cancer	4.32e-07	1.2e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTEN—pancreatic cancer	4.27e-07	1.19e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	4.23e-07	1.18e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTEN—pancreatic cancer	4.23e-07	1.18e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	4.21e-07	1.17e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PPARG—pancreatic cancer	4.07e-07	1.13e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CA—pancreatic cancer	4e-07	1.11e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	3.7e-07	1.03e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CA—pancreatic cancer	3.65e-07	1.01e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AKT1—pancreatic cancer	3.46e-07	9.61e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	3.27e-07	9.09e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AKT1—pancreatic cancer	3.27e-07	9.08e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	3.23e-07	8.97e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTGS2—pancreatic cancer	3.2e-07	8.89e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CA—pancreatic cancer	3.19e-07	8.88e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	3.01e-07	8.36e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	2.98e-07	8.29e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AKT1—pancreatic cancer	2.98e-07	8.28e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTEN—pancreatic cancer	2.79e-07	7.75e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AKT1—pancreatic cancer	2.67e-07	7.43e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AKT1—pancreatic cancer	2.61e-07	7.25e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AKT1—pancreatic cancer	2.46e-07	6.83e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AKT1—pancreatic cancer	2.44e-07	6.77e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.97e-07	5.47e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.61e-07	4.47e-06	CbGpPWpGaD
